Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies.

Patients And Methods: Patients received PS-341 twice weekly for 4 weeks at either 0.40, 1.